Highlights Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.09 ^USD	+2.51%		+10.54%	+44.01%

Mar. 28	Transcript : Humacyte, Inc. - Special Call
Mar. 22	Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	Feb. 09	DJ
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	Feb. 09	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	Feb. 09	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	Feb. 09	CI
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	Dec. 12	CI
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	Nov. 17	CI
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	23-10-16	CI
Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel?? (HAV??) in Treatment of Patients with Vascular Trauma	23-09-12	CI
Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic	23-09-11	CI
Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel from Ukrainian Humanitarian Program	23-08-15	CI
Humacyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel	23-08-03	CI
Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair	23-07-26	CI
Humacyte's Q1 Net Loss Widens; Signs Funding Agreement of Up to $160 Million With Oberland Capital Management	23-05-12	MT
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel(TM) (HAV(TM)) to Treat Vascular Injuries in Ukraine	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Humacyte, Inc.

Equities

HUMA

US44486Q1031

Highlights

Filters